Patient perception and approval of faecal microbiota transplantation (FMT) as an alternative treatment option for obesity

被引:13
|
作者
Gundling, F. [1 ]
Roggenbrod, S. [1 ]
Schleifer, S. [1 ]
Sohn, M. [2 ]
Schepp, W. [1 ]
机构
[1] Tech Univ Munich, Dept Gastroenterol Hepatol & Gastrointestinal Onc, Acad Teaching Hosp Bogenhausen, Englschalkinger St 77, D-81925 Munich, Germany
[2] Univ Munich, Dept Visceral Surg, Acad Teaching Hosp Bogenhausen, Munich, Germany
来源
OBESITY SCIENCE & PRACTICE | 2019年 / 5卷 / 01期
关键词
Fecal microbiota transfer; microbiota obesity; weight loss endoscopy trial (WET); ULCERATIVE-COLITIS; GUT MICROBIOTA; ENERGY-BALANCE; WEIGHT-LOSS; MECHANISMS; DIET;
D O I
10.1002/osp4.302
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Fecal microbiota transplantation (FMT) represents a treatment option for some diseases, e.g. recurring Clostridium difficile-associated colitis. However, there is also evidence that FMT can be effective in treating obesity. This pilot study established the approval and willingness of obese patients to undergo FMT. Methods We conducted a survey of adults with obesity using a questionnaire containing 21 both multiple choice and open questions was dispatched to a cohort of 101 persons with obesity. It included questions aiming at the process of FMT itself, donors as well as possible concerns. Additionally aspects of social background and disease activity were dealt with. Results The response rate amounted to 30.1% (n = 31). In our population, mean BMI was 40.5 kg/m(2) while the vast majority already tried out treatment modalities to lose weight before. 25.8% of persons with obesity were aware of FMT. 62.1% were willing to undergo FMT if the donor was healthy and anonymous while only 6.9% clearly refused this option. Sixty preferred an anonymous donor or a person proposed by their doctor while colonoscopy was the preferred application by 76.7%. The absence of risks of the procedure (47.8%) formed the principal motivation while reduction of medication was considered as least important reason (in 26.1). Insufficient testing of the faeces concerning infections raised the most concerns (in 61.6%). Conclusion For the majority of the persons with obesity surveyed FMT represents a treatment option. Approximately two thirds of the questionees would consider FMT as an alternative treatment option, even in spite of a satisfactory disease response to current standard therapies. Unsurprisingly there are concerns in regard to the transmission of possible infectious agents as well as to the hygieneic implementation of FMT itself.
引用
收藏
页码:68 / 74
页数:7
相关论文
共 50 条
  • [21] Horizontal gene transfer after faecal microbiota transplantation in adolescents with obesity
    Anna H. Behling
    Brooke C. Wilson
    Daniel Ho
    Wayne S. Cutfield
    Tommi Vatanen
    Justin M. O’Sullivan
    Microbiome, 12
  • [22] Increasing the Dose and/or Repeating Faecal Microbiota Transplantation (FMT) Increases the Response in Patients with Irritable Bowel Syndrome (IBS)
    El-Salhy, Magdy
    Hausken, Trygve
    Hatlebakk, Jan Gunnar
    NUTRIENTS, 2019, 11 (06)
  • [23] Faecal butyric acid levels are increased at 2 and 3 years after faecal microbiota transplantation ( FMT) in patients with irritable bowel syndrome (IBS)
    El-Salhy, Magdy
    Valeur, Jorgen
    Bronstad, Ingeborg
    Gilja, Odd Helge
    Hatlebakk, Jan Gunnar
    NEUROGASTROENTEROLOGY AND MOTILITY, 2024, 36
  • [24] Recurrent Campylobacter jejuni Infection in an Immunodeficient Patient Treated with Repeated Faecal Microbiota Transplant (FMT)-A Case Report
    Merrick, Blair
    Tamilarasan, Aravind Gokul
    Luber, Raphael
    Yong, Patrick F. K.
    Cheent, Kuldeep
    Irving, Peter M.
    Meda, Manjula
    Goldenberg, Simon D.
    INFECTIOUS DISEASE REPORTS, 2022, 14 (01) : 56 - 62
  • [25] Fecal microbiota transplantation as a promising treatment option for osteoporosis
    Yuan-Wei Zhang
    Mu-Min Cao
    Ying-Juan Li
    Ruo-Lan Zhang
    Meng-Ting Wu
    Qian Yu
    Yun-Feng Rui
    Journal of Bone and Mineral Metabolism, 2022, 40 : 874 - 889
  • [26] Fecal microbiota transplantation as a promising treatment option for osteoporosis
    Zhang, Yuan-Wei
    Cao, Mu-Min
    Li, Ying-Juan
    Zhang, Ruo-Lan
    Wu, Meng-Ting
    Yu, Qian
    Rui, Yun-Feng
    JOURNAL OF BONE AND MINERAL METABOLISM, 2022, 40 (06) : 874 - 889
  • [27] Should faecal microbiota transplantation be used earlier in the treatment framework?
    Allegretti, Jessica R.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (12): : 1062 - 1063
  • [28] The role of faecal microbiota transplantation in the treatment of inflammatory bowel disease
    Haifer, Craig
    Leong, Rupert W.
    Paramsothy, Sudarshan
    CURRENT OPINION IN PHARMACOLOGY, 2020, 55 : 8 - 16
  • [29] Faecal microbiota transplantation in inflammatory bowel disease: the patient's perspective
    Sousa, M.
    Ponte, A.
    Rodrigues, J.
    Silva, J.
    Gomes, C.
    Rodrigues, A.
    Silva, A. P.
    Carvalho, J.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S355 - S355
  • [30] Clinical and immunologic effects of faecal microbiota transplantation in a patient with collagenous colitis
    Sezin Günaltay
    Lech Rademacher
    Elisabeth Hultgren H?rnquist
    Johan Bohr
    World Journal of Gastroenterology, 2017, 23 (07) : 1319 - 1324